Neurodegenerative DiseasesParkinson DiseaseSynucleinopathiesLewy Body DiseaseMultiple System AtrophyTauopathiesAlzheimer DiseaseCorticobasal DegenerationSupranuclear Palsy, ProgressiveAtypical ParkinsonismTDP-43 ProteinopathiesAmyotrophic Lateral SclerosisFrontotemporal Lobar DegenerationMovement DisordersCognitive ImpairmentDementiaIron OverloadNeurodegeneration With Brain Iron Accumulation (NBIA)
Investigational drug(s) / intervention(s)
Observation
Observation: In MARKERS-NDD up to 600 participants will be enrolled and followed longitudinally once identified, over the course of 1-10 years
Study summary
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.
Eligibility
Sex
ALL
Min age
10 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders
* Patients with diagnosis of Parkinson's Disease
* Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank
* Diagnosis of Movement Disorder not related to Parkinson's Disease
* Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy;
* Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy;
* Diagnosis of Essential Tremor
* Willing to participate in the study, understand the procedures and sign the informed consent.
* Patients affected by cognitive impairment (CI) and dementia
* Diagnosis of probable:
* Lewy Body Dementia
* Alzheimer's Disease
* Mild Cognitive Decline
* Subjective memory complaints
* Willing to participate in the study, understand the procedures and sign the informed consent.
Exclusion Criteria:
* There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.
Primary outcome measure(s)
To monitor and predict the course of neurodegenerative diseases through the study of clinical markers and the creation of AI-models — Baseline to 120 months To identify markers of neurodegenerative disease progression for use in clinical monitoring
Trial sites (1)
Facility
City
Region
Status
San Raffaele Cassino
Cassino
Frosinone
Recruiting
More Casa di Cura San Raffaele Cassino trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
